Fentanyl and its analogs are increasingly contributing to opioid overdoses and deaths across the United States. Since 2017, ToxIC sites have reported multiple cases of such overdoses involving not just fentanyl, but also fluorofentanyl, butyrylfentanyl, and carfentanil.
In April 2020, ToxIC was awarded a 5-year subcontract to the Icahn School of Medicine on a new R01 from the National Institute on Drug Abuse (NIDA). Alex Manini, MD, MS, FACMT, Professor of Emergency Medicine at the Icahn School of Medicine in New York is the Principal Investigator, and Jeffrey Brent, MD, PhD, FACMT, and Paul Wax, MD, FACMT are the co-investigators from ToxIC. The project, entitled "Predicting Medical Consequences of Novel Fentanyl Analog Overdose Using the Toxicology Investigators Consortium (ToxIC)" utilizes high volume geographically diverse ToxIC sites to evaluate risk factors, characterize the novel synthetic opioids used, evaluate the optimal treatments, and track regional trends in fentalog overdoses by using the ACMT ToxIC Registry network.
Fentanyl Analog Contributing Sites
NPS Discovery Dashboard
The Center for Forensic Science Research and Education (CFSRE) provides comprehensive drug molecular identification and quantitation of case samples. The CFSRE's interactive Novel Psychoactive Substance (NPS) Discovery dashboard provides a platform for physicians, researchers, and public health parters to view results based on analytes, class, and demographics.
In partnership with ACMT ToxIC, the CFSRE will assess the role and prevalence of novel substances in participating regions throughout the duration of this project.
Infographic provided by npsdiscovery.org
Archived Quarterly NPS Reports
Public Health Reports
Funding for this initiative was made possible (in part) by grant number 3R01DA048009-01A1S1 from NIH/NIDA/Icahn School of Medicine. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the above; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.